



OPEN ACCESS

Original research

Eradicating *Helicobacter pylori* via ¹³C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method

Wei-Yi Lei,¹ Jian-Yu Lee,² Shu-Ling Chuang,³ Ming-Jong Bair,⁴ Chien-Lin Chen ,¹ Jeng-Yih Wu,⁵ Deng-Chyang Wu,⁵ Felice Tien O'Donnell,⁶ Hui-Wen Tien,⁷ Yi-Ru Chen,⁸ Tsung-Hsien Chiang,⁸ Yu-Hsin Hsu,⁹ Tsui-Hsia Hsu,⁹ Pei-Chun Hsieh,⁹ Li-Ju Lin,⁹ Shu-Li Chia,⁹ Chao-Chun Wu,⁹ Yi-Maun Subeq,¹⁰ Shu-Hui Wen,¹¹ Hsiu-Chun Chang,¹² Yu-Wen Lin,¹³ Kuo-Ping Sun,¹³ Chia-Hsiang Chu,¹⁴ Ming-Shiang Wu,⁸ David Y Graham ,¹⁵ Hsiu-Hsi Chen ,¹⁶ Yi-Chia Lee ^{3,8,16}

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2023-329871>).

For numbered affiliations see end of article.

Correspondence to

Dr Yi-Chia Lee, National Taiwan University College of Medicine, Taipei 10002, Taiwan; yichialee@ntu.edu.tw

W-YL and J-YL are joint first authors.

Received 14 March 2023
Accepted 5 May 2023
Published Online First
17 May 2023



Watch Video
gut.bmj.com



► <http://dx.doi.org/10.1136/gutjnl-2023-330215>



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Lei W-Y, Lee J-Y, Chuang S-L, et al. *Gut* 2023;**72**:2231–2240.

ABSTRACT

Objective Screening and eradication of *Helicobacter pylori* help reduce disparities in the incidence of gastric cancer. We aimed to evaluate its acceptability and feasibility in the indigenous communities and develop a family index-case method to roll out this programme.

Design We enrolled residents aged 20–60 years from Taiwanese indigenous communities to receive a course of test, treat, retest and re-treat initial treatment failures with the ¹³C-urea breath tests and four-drug antibiotic treatments. We also invited the family members of a participant (constituting an index case) to join the programme and evaluated whether the infection rate would be higher in the positive index cases.

Results Between 24 September 2018 and 31 December 2021, 15 057 participants (8852 indigenous and 6205 non-indigenous) were enrolled, with a participation rate of 80.0% (15 057 of 18 821 invitees). The positivity rate was 44.1% (95% CI 43.3% to 44.9%). In the proof-of-concept study with 72 indigenous families (258 participants), family members of a positive index case had 1.98 times (95% CI 1.03 to 3.80) higher prevalence of *H. pylori* than those of a negative index case. The results were replicated in the mass screening setting (1.95 times, 95% CI 1.61 to 2.36) when 1115 indigenous and 555 non-indigenous families were included (4157 participants). Of the 6643 testing positive, 5493 (82.6%) received treatment. According to intention-to-treat and per-protocol analyses, the eradication rates were 91.7% (89.1% to 94.3%) and 92.1% (89.2% to 95.0%), respectively, after one to two courses of treatment. The rate of adverse effects leading to treatment discontinuation was low at 1.2% (0.9% to 1.5%).

Conclusion A high participation rate, a high eradication rate of *H. pylori* and an efficient rollout method indicate that a primary prevention strategy is acceptable and feasible in indigenous communities.

Trial registration number NCT03900910.

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Eradication of *Helicobacter pylori* infection can reduce the gastric cancer risk by about 50%.
- ⇒ Gastric cancer risks are twofold to threefold higher in indigenous individuals. The disparity is exacerbated by their poor uptake of and limited access to the disease prevention strategies.

WHAT THIS STUDY ADDS

- ⇒ Screening and eradication of *H. pylori* are possible and practical in indigenous communities with the structured design, organised execution and stepwise evaluation.
- ⇒ Unhealthy lifestyles are associated with a higher rate of *H. pylori* infection and a lower adherence rate to the programme.
- ⇒ The detection rate of *H. pylori* carriers is increased by twofold using a family index-case method to conduct outreach to the family members of individuals who test positive.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Mass screening using the family index-case method and actions to improve hygiene and lifestyles can accelerate the elimination of *H. pylori*-associated gastric cancer disparities in indigenous communities.

INTRODUCTION

Gastric cancer poses a significant threat to global health, with 1 089 103 new cases and 768 793 related deaths in 2020.¹ A unique feature of gastric cancer is the great variation in incidence rate by race/ethnicity and geography, with the disease tending to be more prevalent in populations with lower socioeconomic status and limited medical resources.² When the resilience of the healthcare systems is being stressed by eventual crisis such as the COVID-19 pandemic,³ pre-existing disparities

are likely to be widened in any healthcare system, especially in one in which the infrastructure is not well prepared to bridge this gap.⁴

Gastric cancers are generated through chronic inflammation, which is mostly initiated by *Helicobacter pylori* infection, and then progresses from chronic gastritis to atrophic gastritis, intestinal metaplasia and eventually to gastric cancer.⁵ The proportions of non-cardiac gastric cancer, cardiac gastric cancer and gastric non-Hodgkin's lymphoma attributable to *H. pylori* have been estimated as about 89%, 29% and 74%, respectively.⁶

In another study based on 512 715 Chinese adults, *H. pylori* infection was associated with about six times higher risk of non-cardiac gastric cancer and three times higher risk of cardiac gastric cancer.⁷ Elucidating the natural course of gastric cancer and the causal role of *H. pylori* infection has prompted a paradigm shift, in which the emphasis traditionally placed on endoscopic early detection has shifted to mass screening and eradication of *H. pylori*. This transition overcomes the previous need to develop an intensive scheme for endoscopic screening and rely on a trained endoscopist workforce, while expanding the ability to arrest the progression of carcinogenesis.^{8–10}

However, despite the unequivocal benefit from *H. pylori* eradication supported by randomised trials, cohort studies and cost-effectiveness analyses,⁹ the population-wide application of this approach, beyond the scope of individual treatment, is rarely realised.¹¹ This gap partly results from the fact that the number of *H. pylori*-infected individuals tends to be large, without a sustainable goal with a staggered increase in the coverage rate; the result may be an unaffordable burden in the subsequent management of those who test positive. It is partly because the incidence of gastric cancer, correlating with the prevalence rate of *H. pylori* infection, differs so geographically and racially that such a programme needs to take into consideration the barriers resulting from cultural, administrative, geographical and economic distances.^{4, 12} Moreover, without the collaboration of healthcare policymakers, frontline general practitioners and the residents themselves, it is difficult to ensure that the quality of screening services can meet the population's expectations and that the programme can be made sustainable.¹³

Gastric cancer disparities are common in indigenous populations, such as Indigenous Australians, Maori in New Zealand, indigenous peoples from the circumpolar region, Native Americans and Alaska natives in the USA, and the Mapuche peoples in Chile; all show a disproportionately higher incidence rate than that of their non-indigenous counterparts.¹⁴ A similar situation exists for the Taiwanese indigenous peoples, accounting for about 2.4% of the whole Taiwanese population. Their prevalence rate of *H. pylori* infection is as high as 60%, which is accompanied by an age-standardised gastric cancer incidence rate twofold to threefold higher than that of the overall population.¹⁵ To tackle this cancer health disparity, a mass screening and eradication programme has been ongoing in Taiwanese indigenous communities. Using this unique opportunity, we tested the hypothesis that mass screening and eradication of *H. pylori* could be made acceptable and feasible for them. In addition, we developed a family index-case method as a means to roll out this programme.

METHODS

Study population and design of the programme

Our target population was the residents living in the 55 indigenous townships (736 tribes) in Taiwan.¹⁶ Screening was designed as once in a lifetime for adults aged 20–60 years, at least 5 years before the mean age of gastric cancer diagnosis in indigenous

peoples.¹⁵ The workflow of the screening programme was developed by a multidisciplinary team that consisted of medical specialists, public health experts and indigenous culturists. To overcome the cultural distance, the team design, team launch and team process management were audited by a committee with representative members familiar with indigenous health-care and culture, which was organised by policymakers from Health Promotion Administration (HPA), Taipei City, Taiwan.¹⁷

Prior to the screening, staff of the public health bureaus in charge of the indigenous townships were invited by HPA to join the programme. To overcome the geographical distance, a series of team-designed education activities were disseminated to the frontline physicians and public health workers. The target number of participants for each community was based on the local healthcare workforce and the annual budget. The HPA provided the population list and eligible residents were invited by the public health centres with self-designed approaches to receive screening for *H. pylori* infection. Pregnant or lactating women and patients with major comorbid diseases were excluded.

Upon screening, each participant's demographic data, social habits, family history and medical history were recorded and stored in an on-premises hosted software system (International Integrated Systems, Taipei City, Taiwan), in which the individual screening process could be traced, including the initial test results, referral to treatment, antibiotic regimens, compliance with treatment, occurrence of side effects and the retest results.¹⁸ A phone call contact method was used to assess the compliance with antibiotic treatment and evaluate the occurrence of side effects.¹⁹ Aggregating the above information generated the standardised quality indicators, so as to identify the bottlenecks in the workflow processes and overcome the administrative distance.

The reinfection of *H. pylori* had the potential to reduce the efficacies of the mass eradication programme.²⁰ Two years after successful eradication therapy, about 10% of participants were randomly selected from each community to receive retests to determine the reinfection rate.²¹

Development of the family index-case method

Most of our eligible subjects lived in either remote or high-mountain areas, so an efficient method was needed to increase the detection rate of *H. pylori*, given the limited resources. An index-case method was therefore proposed based on the clustering of *H. pylori* infection in families, related to the person-to-person transmission.^{22–24} After the initial screening, the family members of those testing positive for *H. pylori* (constituting the positive index cases) would be subsequently contacted to receive screening. We only included family members who lived together in the same house. We hypothesised that, following this approach, the detection rate of *H. pylori* infection based on the positive index cases would be higher than that based on the negative index cases.²⁵ We selected a representative indigenous township to initiate a proof-of-concept study. Then, we verified the results in the mass screening setting when participants from different townships were enrolled.

Screening and treatment for *H. pylori*

The screening and treatment were provided free of charge, overcoming the economic distance. In subjects who had fasted for at least 4 hours, *H. pylori* infection was documented via the ¹³C-urea breath test (Hwang's Pharmaceutical Company, Yunlin County, Taiwan). The test was chosen because of its non-invasiveness, relative ease of use and the high stability of isotope 13 carbon in storage and transport, in addition to a high

sensitivity and specificity of 95% or more.²⁶ Baseline and 30 min breath samples were assayed with an infrared spectrometer that produced computer-generated results in the certified laboratory (Taipei Institute of Pathology, Taipei City, Taiwan). Patients with inconclusive results received another ¹³C-urea breath test. For the initial screenees, the family index-case method would be suggested to invite his/her family members to join the programme.

There was one public health centre in each indigenous township. With a standard print report, those who tested positive for *H. pylori* were contacted by the staff of public health centres and referred to the nearest or the most convenient public health centre to receive the anti-*H. pylori* treatment: a four-drug treatment course for 14 days (lansoprazole 30 mg plus amoxicillin 1 g for the first 7 days, followed by lansoprazole 30 mg, clarithromycin 500 mg and metronidazole 500 mg for another 7 days; all drugs given orally two times per day). This regimen was chosen as the first-line treatment because most participants either did not report any associated symptoms or were treatment-naïve for the eradication treatments. The sequential schedule was advantageous in identifying the drug, among a multidrug combination, responsible for any side effects or allergic reactions that occurred, in addition to showing an eradication rate as high as >90%.²⁷ Post-treatment, *H. pylori* status was assessed by another ¹³C-urea breath test at 6–8 weeks after completion of treatment. For subjects with an allergic history to certain antibiotics, an alternative three-drug or four-drug treatment, replacing the allergic one, was prescribed. To facilitate the above process, a teleconsultation service was developed for the healthcare workers with the LINE group that enabled instant communication with the experts. The current health insurance in Taiwan did not reimburse the eradication treatment without an endoscopic diagnosis of peptic ulcers. Therefore, the medications, with the standardised regimen, dose and duration, were distributed from National Taiwan University Hospital after a centralised bidding process, ensuring the quality of treatment. We did not differentiate the treatment regimen depending on whether an eradication has been received previously because the information could not be ascertained. During treatment, we advised participants to reduce smoking as much as possible to increase the chances of successful treatment.²⁸

Those who did not respond to the initial course were re-treated with a bismuth-based four-drug treatment for 10 days (lansoprazole 30 mg two times per day, bismuth (III) oxide 120 mg four times a day, amoxicillin 500 mg four times a day and tetracycline 500 mg four times a day; all drugs given orally).²⁹ For subjects who could not tolerate the bismuth-based treatment, a 10-day levofloxacin-based three-drug treatment (lansoprazole 30 mg two times per day, amoxicillin 1 g two times per day and levofloxacin 500 mg once daily; all drugs given orally) was prescribed. Cases with alarming symptoms or who failed two courses of antibiotic treatments were referred to the nearest hospital with facilities for endoscopic examination. In addition to any suspicious lesions, biopsy specimens (one from the gastric antrum and the other one from gastric body)³⁰ were collected and cultured on plates containing *Brucella* chocolate agar with 7% sheep blood and incubated for 14 days under microaerobic conditions. The minimum inhibitory concentrations were determined by the agar dilution test in the laboratory of the National Taiwan University Hospital or Kaohsiung Medical University Hospital. The resistance cut-off values for amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin were defined as greater than 0.5, 1.0, 8.0, 0.5 and 1.0 mg/L, respectively.³¹ The test was done to monitor the prevalence of antibiotic resistant strains or,

in patients with repeated treatment failure, to design a tailored regimen.

Outcome

Our outcome was the acceptability and feasibility of this screening programme to achieve eradication, which was evaluated by answering whether the screening quality indicators could reach the minimal requirements set up by the team (online supplemental figure 1), beginning from completing a participation rate of ≥60%, attaining a positivity rate of ≥40%, receiving a referral-to-treatment rate of ≥60%, to achieving an eradication rate of ≥80%.

Statistical analysis

For baseline characteristics, categorical data were expressed as a percentage (%) and continuous data were expressed as mean (IQR). We compared categorical data using the χ^2 test and compared continuous data with the Student's t-test. The performance of the family index-case approach was verified by making a comparison of the *H. pylori* infection rates between the family members of the positive and negative index cases. Results were expressed as crude and adjusted ORs and the corresponding 95% CIs in a generalised estimating equation, taking into account the correlation within the family.³²

For the screening quality indicators, the participation rate was defined as the number of participants divided by the number of invitees. The positivity rate was calculated as the number of positive test results divided by the number of participants. The referral-to-treatment rate was calculated as the number of individuals who received anti-*H. pylori* treatment divided by the number of positive test results. The intention-to-treat (ITT) and per-protocol (PP) analyses were carried out to assess the eradication rates. All patients who received anti-*H. pylori* treatment were included in the ITT analysis; the PP analysis included those who took more than 80% of treatment drugs or whose post-treatment *H. pylori* status was known. Univariate and multivariate logistic regression analyses were performed for each quality indicator to identify the risk factors significantly associated with the quality of screening. Results were expressed as crude and adjusted ORs and the corresponding 95% CIs. We applied the complete case analyses by removing missing data from the regression analyses as only about 5% of records were missing in the questionnaire data.

The reinfection rate was defined as the number of positive test results divided by the person-years of follow-up. Poisson regression analyses were used to evaluate the risk factors for reinfection. Statistical analyses were performed using SAS V.9.4 (SAS Institute). P values of <0.05 were considered statistically significant.

Role of the funding source

Staff from HPA were not only involved in this study as the funding source but also served as collaborators who made contributions to the design of the programme, the audit of quality indicators, the interpretation of results and the decision to submit this paper for publication.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

RESULTS

The participation rate and baseline data

Between 24 September 2018 and 31 December 2021, a total of 18812 eligible subjects were invited in 40 of 55 indigenous

Table 1 Baseline characteristics of participants to the gastric cancer prevention programmes, with relationship to *Helicobacter pylori* infection

Baseline characteristics*	Indigenous peoples (N=8852)		Non-indigenous peoples (N=6205)	
	No of subjects	No of <i>H. pylori</i> carriers (%)	No of subjects	No of <i>H. pylori</i> carriers (%)
	8852	5055 (57.1)	6205	1588 (25.6)
Age, in years				
20–29	1221	620 (50.8)	737	82 (11.1)
30–39	2047	1129 (55.2)	1412	283 (20.0)
40–49	2470	1471 (59.6)	1979	532 (26.9)
50–60	3114	1835 (58.9)	2077	691 (33.3)
Sex				
Male	3144	1846 (58.7)	2313	609 (26.3)
Female	5708	3209 (56.2)	3892	979 (25.2)
Social habits				
Smoking				
Current	2269	1413 (62.3)	623	209 (33.5)
Former	1046	593 (56.7)	474	160 (33.8)
Never	5537	3049 (55.1)	5108	1219 (23.9)
Alcohol use				
Current	4905	2934 (59.8)	1671	486 (29.1)
Former	853	481 (56.4)	266	95 (35.7)
Never	3094	1640 (53.0)	4268	1007 (23.6)
Betel nut chewing				
Current	2468	1590 (64.4)	266	96 (36.1)
Former	990	589 (59.5)	313	102 (32.6)
Never	5394	2876 (53.3)	5626	1390 (24.7)

*The family history, medical history and ethnic groups are shown in the online supplemental table 1.

townships (representing 454 of 736 tribes) in Taiwan. Of these, a total of 15 057 participated (a participation rate of 80.0%, 95% CI 79.4% to 80.6%). There were no significant differences between participants and non-participants in terms of age ($p=0.97$) and sex ($p=0.99$). The most successful invitation strategies included the clinical services at the public health centres (22.4%), health screening services (21.8%), social activities (20.6%), telephone (20.0%), social media (9.7%) and the mail/email (5.5%).

Baseline characteristics of participants are shown in table 1 and online supplemental table 1. Overall, 9600 (63.8%) were women, with a mean age of 44.5 years (IQR 35.7–53.0). When we stratified the data into indigenous ($n=8852$) and non-indigenous subjects ($n=6205$), there were non-significant differences in the distribution of age, sex, family history related to *H. pylori*-associated diseases and medical history, except that the indigenous subjects had a higher prevalence of the social habits of smoking, alcohol drinking and betel nut chewing.

Positivity rates for *H. pylori* infection

Overall, the *H. pylori* positivity rate was 44.1% (95% CI 43.3% to 44.9%). Indigenous peoples had a higher positivity rate (57.1%) than that of their non-indigenous counterparts (25.6%) (table 1). The positivity rates increased with age. Those who had the habits of smoking, alcohol drinking and betel nut chewing had higher positivity rates. Those with a history of *H. pylori* infection had a lower positivity rate, likely related to their previous eradication treatments (online supplemental table 1).




Figure 1 Prevalence rates of *Helicobacter pylori* infection by the age ranges (20–29, 30–39, 40–49 and ≥50 years), stratified by indigenous status.

When the data were stratified according to age range and indigenous status (figure 1), we found that the indigenous subjects aged 20–29 years already had a high infection rate (>50%), which then plateaued with age. By contrast, the infection rate in the non-indigenous subjects steadily increased with age from about 10% to 30%. These results may suggest that the intrafamilial transmission of *H. pylori* was more prevalent in indigenous families during childhood and adolescence.

Multivariable regression analyses (figure 2) consistently showed that the indigenous peoples had a significantly higher risk of *H. pylori* infection, whether they lived in the mountain areas or in the plains areas (adjusted ORs 3.59, 95% CI 3.25 to 3.95 and 2.24, 95% CI 1.96 to 2.55, respectively), as compared with non-indigenous peoples. Older age, current and former smoking (adjusted ORs 1.19, 95% CI 1.05 to 1.35 and 1.17, 95% CI 1.00 to 1.37, respectively, compared with never smoking), current alcohol drinking (adjusted OR 1.21, 95% CI 1.09 to 1.34, compared with never use), and current and former betel nut chewing (adjusted ORs 1.54, 95% CI 1.35 to 1.75 and 1.24, 95% CI 1.05 to 1.47, respectively, compared with never use) were also significantly associated with a higher positivity rate.

Verification of the family index-case method

This approach was first evaluated in Wulai District (New Taipei City, Taiwan). In this proof-of-concept study, a total of 72 index cases participated in the initial screening, including 48 tested positive for ¹³C-urea breath test (the positive index case) and 24 tested negative (negative index case). The mean number of relatives per family was 3.6 (IQR: 2). Two representative family structures are shown in figure 3. The infection–pedigree relationships of 258 participants (72 families) are shown in the online supplemental table 2A. The results indicated that family members from the positive index case were associated with a higher risk of *H. pylori* infection than those of the negative index cases (adjusted OR 1.98, 95% CI 1.03 to 3.80), adjusted for the age, sex and smoking habit (online supplemental table 3A). Current and former smokers were also associated with the higher risk than never smokers (adjusted OR 2.87, 95% CI 1.17 to 7.02 and 2.87, 95% CI 1.31 to 6.33, respectively).

There were 43 couples, 27 siblings and 97 parent–child relationships among the 72 families. Their consanguinity relationships are shown in online supplemental table 2B. The positive index case was significantly associated with a higher risk of infection in his/her parent or children (OR 2.89, 95% CI 1.18 to




Figure 2 Risk factors associated with 6643 positive results of the ¹³C-urea breath tests among 15057 participants in the indigenous communities. The multivariable model, adjusted for all variables, is shown in the forest plot. An OR greater than 1.0 (dotted line) indicates an increased risk of *Helicobacter pylori* (*H. pylori*) infection.

7.05, $p=0.02$) than the negative index case. A higher infection risk was seen in the siblings (OR 2.08, 95% CI 0.39 to 11.06, $p=0.39$) but the result was not significant due to the small case




Figure 3 The infection–pedigree relationships of two indigenous families in the proof-of-concept study to demonstrate the rationale of the family index-case method. The prevalence rate of *Helicobacter pylori* infection in the family members of the positive index case will be about twofold higher than that in the family members of the negative index case due to intrafamilial transmission. The two families are the numbers 48 and 59 shown in the online supplemental table 2A.

number. There was no significant difference in the couples (OR 1.08, 95% CI 0.28 to 4.13, $p=0.91$).

In the mass screening setting, there were 1670 initial screenees (777 positive and 893 negative index cases) who had subsequent family outreach, totalling 4157 individuals (4157 of 15 057, 27.6%) within 1115 indigenous and 555 non-indigenous families. Consistently, family members of the positive index case were associated with a higher risk of *H. pylori* infection than those of the negative index cases (adjusted OR 1.95, 95% CI 1.61 to 2.36, adjusted for the age, sex, indigenous status and smoking habit) (online supplemental table 3B). Older age, indigenous people and current smokers were also associated with the higher risk (adjusted ORs 1.22, 95% CI 1.13 to 1.32; 2.31, 95% CI 1.88 to 2.84; and 1.51, 95% CI 1.20 to 1.90, respectively).

Referral-to-treatment rates

Among the 6643 subjects testing positive, 5493 (82.7%) were successfully referred to receive anti-*H. pylori* treatment. The results, stratified by age, sex and indigenous status, are shown in the online supplemental table 4 and indicated that indigenous subjects (adjusted ORs 1.70, 95% CI 1.26 to 2.29 and 2.53, 95% CI 1.89 to 3.40, respectively, for the mountain and plains indigenous subjects) and those in younger age groups had lower referral-to-treatment rates (relative to the 20–29 years age




Figure 4 Risk factors associated with the 1150 non-referrals among 6643 participants who tested positive for *Helicobacter pylori* (*H. pylori*) infection. The multivariable model, adjusted for all variables, is shown in the forest plot. An OR greater than 1.0 (dotted line) indicates an increased risk of non-referral to treatment.

group: 30–39 years: adjusted OR 0.69, 95% CI 0.55 to 0.88; 40–49 years: adjusted OR 0.58, 95% CI 0.46 to 0.73; and 50–60 years: adjusted OR 0.49, 95% CI 0.39 to 0.62 (figure 4). Use of antiplatelet (adjusted OR 2.29, 95% CI 1.06 to 4.96) and anticoagulant drugs (adjusted OR 2.72, 95% CI 1.30 to 5.73) was also associated with a lower referral-to-treatment rate, likely related to the presence of comorbidities. Current smokers also had a lower referral-to-treatment rate (adjusted OR 1.45, 95% CI 1.19 to 1.78).

Eradication rates

According to the ITT and PP analyses, the eradication rates were 91.7% (95% CI 89.1% to 94.3%) and 92.1% (89.2% to 95.0%), respectively, after one or two courses of treatment (table 2). Specifically for the first-line treatment, the eradication rates were 78.5% (76.3% to 80.8%) and 79.5% (77.2% to 81.7%) in the ITT and PP analyses, respectively; the results for the second-line treatment were 61.3% (59.6% to 63.1%) and 61.3% (59.4% to 63.3%), respectively. Multivariable regression analyses of the first-line treatment indicated that males were less likely associated with treatment failure (adjusted OR 0.82, 95% CI 0.68 to 0.98). Treatment failure was significantly associated with having a history of peptic ulcer (adjusted OR 1.35, 95% CI 1.02 to 1.79), having a history of *H. pylori* infection (adjusted OR 1.70, 95% CI 1.14 to 2.54) and current smoking (adjusted OR 1.38, 95% CI 1.10 to 1.73, compared with never smoking) (figure 5).

However, the former smokers were not associated with the risk of treatment failure (adjusted OR 1.17, 95% CI 0.88 to 1.57, compared with never smoking).

The results for the PP analyses were mostly similar (online supplemental figure 2). Those who used iron supplements had a lower risk of eradication failure (adjusted OR 0.33, 95% CI 0.12 to 0.92) in the ITT analyses but not in the PP analyses (adjusted OR 0.38, 95% CI 0.14 to 1.07). Majority of subjects (155 of 166, 93.4%) who used the iron supplement were female, likely for the indication of iron-deficiency anaemia related to the gynaecological diseases. Being in an older age group was associated with a lower risk of treatment failure (compared with those aged 20–29: 40–49 years: adjusted OR 0.62, 95% CI 0.47 to 0.82; 50–60 years: adjusted OR 0.76, 95% CI 0.58 to 0.99). However, this significance was not observed in the PP analyses, which could be explained by the lower compliance-to-treatment rate in the younger age groups.

Side effects were generally uncommon but included allergic reaction (0.4%), nausea and vomiting (1.2%), headache (1.0%), diarrhoea (1.1%), and epigastric pain and poor appetite (0.4%). The rate of adverse effects leading to treatment discontinuation was low at 1.2% (95% CI 0.9% to 1.5%).

Antibiotic resistance rates

A total of 334 *H. pylori* carriers underwent antibiotic susceptibility tests to evaluate the primary resistance rates (table 3). The

Table 2 *Helicobacter pylori* eradication rates after one or two courses of antibiotic treatments, stratified by age and sex

Baseline characteristics	No of participants	Test positive, no (%)	Referral, no (%)	Eradication rate, intention-to-treat analysis, % (95% CI)*	Eradication rate, per-protocol analysis, % (95% CI)†
Indigenous peoples					
Male					
20–39	1197	648 (54.1)	499 (77.0)	89.6 (84.7 to 94.8)	92.1 (87.0 to 97.5)
40–60	1947	1198 (61.5)	974 (81.3)	92.5 (88.4 to 96.7)	92.4 (88.4 to 96.6)
Subtotal	3144	1846 (58.7)	1473 (79.8)	91.5 (88.4 to 94.8)	92.2 (89.1 to 95.5)
Female					
20–39	2071	1101 (53.2)	876 (79.6)	87.4 (83.8 to 91.3)	88.9 (85.2 to 92.8)
40–60	3637	2108 (58.0)	1802 (85.5)	91.5 (88.5 to 94.5)	91.1 (88.2 to 94.1)
Subtotal	5708	3209 (56.2)	2678 (83.5)	90.2 (87.9 to 92.6)	90.4 (88.1 to 92.8)
Both sexes					
20–39	3268	1749 (53.5)	1375 (78.6)	88.2 (85.2 to 91.2)	90.0 (87.0 to 93.1)
40–60	5584	3306 (59.2)	2776 (84.0)	91.8 (89.4 to 94.2)	91.6 (89.2 to 94.0)
Total	8852	5055 (57.1)	4151 (82.1)	90.7 (88.8 to 92.6)	91.0 (89.2 to 93.0)
Non-indigenous peoples					
Male					
20–39	856	148 (17.3)	123 (83.1)	93.5 (87.5 to 100)	93.8 (87.7 to 100)
40–60	1457	461 (31.6)	394 (85.5)	93.6 (88.9 to 98.6)	94.2 (89.5 to 99.2)
Subtotal	2313	609 (26.3)	517 (84.9)	93.6 (89.9 to 97.5)	94.2 (90.4 to 98.1)
Female					
20–39	1293	217 (16.8)	179 (82.5)	91.8 (86.9 to 97.0)	88.8 (84.0 to 93.7)
40–60	2599	762 (29.3)	646 (84.8)	96.1 (92.5 to 99.9)	96.3 (92.7 to 100)
Subtotal	3892	979 (25.2)	825 (84.3)	95.3 (92.4 to 98.3)	95.4 (92.4 to 98.4)
Both sexes					
20–39	2149	365 (17.0)	302 (82.7)	92.6 (88.7 to 96.6)	91.2 (87.4 to 95.2)
40–60	4056	1223 (30.2)	1040 (85.0)	95.1 (92.2 to 98.1)	95.5 (92.6 to 98.5)
Total	6205	1588 (25.6)	1342 (84.5)	94.6 (92.3 to 97.0)	94.9 (92.6 to 97.3)
Overall	15057	6643 (44.1)	5493 (82.7)	91.7 (89.1 to 94.3)	92.1 (89.2 to 95.0)

*The intention-to-treat analysis includes those who received the *H. pylori* eradication.

†The per-protocol analysis includes those who received the *H. pylori* eradication and took at least 80% of medication.

resistance rates to amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin were 7.2%, 26.0%, 39.2%, 6.6% and 25.5%, respectively. The resistance rates did not significantly differ by age (20–39 vs 40–60 years). However, results stratified by sex indicated that females had a higher rate of resistance to metronidazole (47.8% vs 26.0%, $p < 0.001$) and to tetracycline (8.9% vs 3.1%, $p = 0.048$), which may explain the lower eradication failure rate in males in both the ITT and PP analyses (figure 5 and online supplemental figure 2).

Reinfection rates

Among 498 cases who received successful eradication therapy, 25 cases had documented reinfection (online supplemental table 5). Over the 1569 person-years of follow-up, the reinfection rate was estimated as 1.59% (95% CI 1.08% to 2.34%). Indigenous subjects had a higher risk of reinfection than their non-indigenous counterparts (rate ratio 3.07, 95% CI 0.72 to 13.2). The social habits of current and former smoking (rate ratios 2.72, 95% CI 1.03 to 7.16 and 3.09, 95% CI 1.18 to 8.31, respectively, compared with never smoking), current alcohol drinking (rate ratio 2.69, 95% CI 1.01 to 7.17, compared with never use), and current and former betel nut chewing (rate ratios 3.59, 95% CI 1.52 to 8.45 and 3.25, 95% CI 1.02 to 10.36, compared with never use) were significantly associated with a higher risk of reinfection (online supplemental figure 3).

DISCUSSION

Taiwanese indigenous peoples are linguistically and culturally associated with Austronesia. Their communal lifestyles and pan-spiritual traditional beliefs form a unique social system and interpersonal network.³³ In addition to the economic and social inequalities, they have experienced limited access to the qualified and timely healthcare. In the present study, with a three-tier foundation of input from policymakers, frontline general practitioners and the target communities, we prove that mass screening and eradication of *H. pylori* are achievable in indigenous communities where the barriers to any preventive intervention are generally the greatest. In addition to the foreseeable benefit from *H. pylori* eradication in a highly prevalent area, our programme provides a pragmatic method that can be readily generalised to other populations with similar gastric cancer health disparities, by reaching out to the family members of *H. pylori* carriers, mapping out the processes of screening and relieving any bottlenecks in resource allocation, to maximise the throughput and create a sustainable system.

There are two kinds of gastric cancer preventive interventions: primary prevention with screening and eradication of *H. pylori* infection, and secondary prevention with periodical endoscopic screening.³⁴ In this study designed for disadvantaged minorities using the first approach, we noted a high prevalence rate of *H. pylori* infection, together with the presence of multiple unhealthy lifestyle factors that may simultaneously




Figure 5 Risk factors associated with the 1024 treatment failures among 5493 subjects who received the first-line treatment for *Helicobacter pylori* (*H. pylori*) infection, according to the intention-to-treat analyses. The multivariable model, adjusted for all variables, is shown in the forest plot. An OR greater than 1.0 (dotted line) indicates an increased risk of treatment failure.

increase the risk of other cancers in the upper aero-digestive tract, such as oral cancer, hypopharyngeal cancer, oesophageal cancer and lung cancer. Similarly, these demonstrated cancer health disparities collectively contribute to the lower life expectancy of indigenous populations, about 8 years on average.³⁵ The higher infection rate in the indigenous peoples was likely related to the oral–oral, faecal–oral or gastro–oral transmission prevalent in the families,³⁶ which was supported by their higher infection rate in the young age group and the higher possibility of coinfection in the parent/children and sibling relationships than that in the couples. This should be prevented by improving hygiene behaviours.

Furthermore, not only are unhealthy lifestyle habits associated with a higher positivity rate of *H. pylori* infection, they are also associated with a lower referral-to-treatment rate, a lower eradication rate and a higher reinfection rate, slowing down the system workflow. Therefore, our study indicated that improving stomach health can serve as an opportunity to raise population awareness about the importance of health-promotion lifestyles and provide synergic effects to improve upper digestive tract health as a whole.³⁷

Two interesting findings were observed regarding the efficacies of antibiotic treatment. First, only the habit of active smoking but not the former smoking or the never smoking was significantly associated with treatment failure, which lent support to the fact that smoking can increase the acidity of the stomach, increasing

the proportion of non-replicative bacteria and making it more difficult for antibiotics to work effectively.²⁸ Although we have advised the smokers to minimise smoking during treatment, the higher failure rate indicated the poor adherence to this advice. Second, *H. pylori* infection has been documented as a potential cause of iron-deficiency anaemia and treatment failure of iron supplementation.³⁸ In our study, we did not ask the participants to stop iron supplements during *H. pylori* eradication although gastric acid was required to increase the solubility and uptake of ferric iron. Surprisingly, we observed a better eradication rate in the users of iron supplements. As iron is essential for bacterial replication,³⁹ we suspected that the iron supplements may promote the growth of *H. pylori* into the replicative phase when it is more susceptible to the antibiotic treatment. This assumption requires further observations.

The strengths of our study include a healthcare system-level approach in delivering an organised screening service, an efficient approach in increasing the detection of *H. pylori* infection, quality assurance with the design of standardised performance indicators that are digitally assessable and the evaluation of outcomes in the context of a pragmatic study in indigenous communities. The similar magnitude of infection risk observed in both the indigenous or non-indigenous families supported the generalisability of the family index-case method. However, our study has limitations. First, it is known that the eradication rate of *H. pylori* is determined by patient compliance with treatment

Table 3 Primary antibiotic resistance rates of *Helicobacter pylori* in the Taiwanese indigenous communities

MIC analyses*	Primary resistance rate of <i>H. pylori</i>		
	Male (n=131)	Female (n=203)	Total (n=334)
Amoxicillin			
Age, in years			
20–39	4/24 (16.7%)	0/43 (0%)	4/67 (6.0%)
40–60	6/107 (5.6%)	14/160 (8.8%)	20/267 (7.5%)
Total	10/131 (7.6%)	14/203 (6.9%)	24/334 (7.2%)
Clarithromycin			
Age, in years			
20–39	8/24 (33.3%)	9/43 (20.9%)	17/67 (25.4%)
40–60	23/107 (21.5%)	47/160 (29.4%)	70/267 (26.2%)
Total	31/131 (23.7%)	56/203 (27.6%)	87/334 (26.0%)
Metronidazole			
Age, in years			
20–39	6/24 (25.0%)	21/43 (48.8%)	27/67 (40.3%)
40–60	28/107 (26.2%)	76/160 (47.5%)	104/267 (39.0%)
Total	34/131 (26.0%)	97/203 (47.8%)	131/334 (39.2%)
Tetracycline			
Age, in years			
20–39	2/24 (8.3%)	3/43 (7.0%)	5/67 (7.5%)
40–60	2/107 (1.9%)	15/160 (9.4%)	17/267 (6.4%)
Total	4/131 (3.1%)	18/203 (8.9%)	22/334 (6.6%)
Levofloxacin			
Age, in years			
20–39	6/24 (25.0%)	13/42 (31.0%)	19/66 (28.8%)
40–60	30/106 (28.3%)	35/157 (22.3%)	65/263 (24.7%)
Total	36/130 (27.7%)	48/199 (24.1%)	84/329 (25.5%)

*The resistance cut-off values for amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin were defined as greater than 0.5, 1.0, 8.0, 0.5 and 1.0 mg/L, respectively.
MIC, minimum inhibitory concentration.

and by bacterial resistance to antibiotics.⁴⁰ Although our overall eradication rate could reach 90% after a test–treat–retest–re-treat course, there was room for improvement. As the efficacies of the ITT and PP analyses were similar to each other, our findings indicated that the major obstacle was the higher antibiotic resistance rates in the indigenous communities. Consistently, the observed resistance rates to amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin were 7.2%, 26.0%, 39.2%, 6.6% and 25.5%, respectively, which were all higher than those observed in the general Taiwanese population (2.4%, 16.0%, 28.5%, 2.4% and 11.1%, respectively).^{27–29} Solutions may include the selection of a regimen with a higher potency of acid suppression, a higher dose/duration of antibiotics or the use of less exposed antibiotics; choices must be weighed in the light of population compliance and follow the principle of antibiotic stewardship.⁴¹ Second, similar to those designed for the screening of other prevalent cancers,⁴² our quality indicators are readily generalisable for mass screening and eradication for *H. pylori* infection; however, the minimal requirement levels may need to be adjusted in a compliance-resistant population. Finally, the long-term goal of this programme is to reduce the rate of newly occurring gastric cancer,⁴³ which requires continuous observation of the trend in gastric cancer incidence and quantification of the magnitude of any declines, as adopted in our previous study with the number needed to treat of about 170 to prevent one gastric cancer.^{9–11}

In conclusion, our study indicates that our plan for the mass screening and eradication of *H. pylori* is acceptable and feasible for the minority ethnic groups in Taiwan with a high prevalence of *H. pylori* infection and a high incidence of gastric cancer. The various barriers to success can be overcome by placing a strong foundation, developing an efficient method and auditing the quality indicators for screening. This plan of action provides the essential details to improve gastric cancer control by eliminating exposure to risk factors, efficiently reducing the existing health inequalities of this infection-associated cancer.

Author affiliations

¹Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien County, Taiwan
²Wulai District Public Health Center, Department of Health, New Taipei City Government, New Taipei City, Taiwan
³Department of Medical Research, National Taiwan University Hospital, Taipei City, Taiwan
⁴Division of Gastroenterology, Department of Internal Medicine, Taitung branch of Mackay Memorial Hospital, Taitung County, Taiwan
⁵Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan
⁶Department of Emergency and Critical Care Medicine, Cheng Hsin General Hospital, Taipei City, Taiwan
⁷Sioulin District Public Health Center, Hualien County Health Bureau, Hualien County, Taiwan
⁸Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan
⁹Health Promotion Administration, Ministry of Health and Welfare, Taipei City, Taiwan
¹⁰Department of Nursing, College of Health, National Taichung University of Science and Technology, Taichung City, Taiwan
¹¹Department of Public Health, Tzu Chi University, Hualien County, Taiwan
¹²Public Health Bureau, Pingtung County Government, Pingtung County, Taiwan
¹³Public Health Bureau, Taitung County Government, Taitung County, Taiwan
¹⁴Hualien County Health Bureau, Hualien County Government, Hualien County, Taiwan
¹⁵Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
¹⁶Division of Biostatistics, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan

Acknowledgements The authors would like to thank the physicians, nurses and frontline healthcare workers in the public health centres in the indigenous townships and the public health bureaus in Taitung County, Hualien County, New Taipei City, Yilan County, Taoyuan City, Hsinchu County, Miaoli County, Taichung City, Nantou County, Chiayi County, Kaohsiung City and Pingtung County for their commitment and contributions to this programme. The programme execution and result interpretations have also benefited from the thorough discussion in the Council of Indigenous Peoples in Taiwan on 23 February 2023.

Contributors All authors had full access to the data and took responsibility for the integrity of the data and the accuracy of the data analysis. Conception and design of the study—T-HH, L-JL, S-LC, C-CW, H-HC and Y-CL. Generation, collection, assembly, analysis and/or interpretation of data—all authors. Statistical analysis—S-LC, H-HC and Y-CL. Drafting or revision of the manuscript—W-YL, J-YL, DYG, H-HC and Y-CL. Clinical reasoning and critical revision of the manuscript for important intellectual content—all authors. Administrative, technical or material support—H-WT, Y-HH, T-HH, P-CH, L-JL, S-LC, C-CW, H-CC, Y-WL, K-PS and C-HC. Approval of the final version of the manuscript—all authors. Study supervision—Y-CL. Y-CL had the final responsibility for the decision to submit for publication. Y-CL was responsible for the overall content as the guarantor.

Funding This study was supported by the Health Promotion Administration, Ministry of Health and Welfare, Taiwan (A1111008).

Competing interests DYG is an unpaid consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel *Helicobacter pylori* therapies and has previously received research support for culture of *H. pylori*. He is also a consultant with Janssen Research & Development regarding potential gastrointestinal effects of drugs under development and has collaborated on research projects with American Molecular regarding molecular diagnostics for *H. pylori*.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Obtained.

Ethics approval This study involves human participants and the Research Ethics Committee of National Taiwan University Hospital (201804108RINB) and the Council

of Indigenous Peoples in Taiwan (1070056368) approved the protocol for this project. The informed consent has been obtained from each participant.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Most data relevant to the study are included in the article or uploaded as supplemental information. Additional data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Chien-Lin Chen <http://orcid.org/0000-0002-9084-8210>

David Y Graham <http://orcid.org/0000-0002-6908-8317>

Hsiu-Hsi Chen <http://orcid.org/0000-0002-5799-6705>

Yi-Chia Lee <http://orcid.org/0000-0002-8160-1216>

REFERENCES

- Sung H, Ferlay J, Siegel RL, *et al*. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.
- Ward E, Jemal A, Cokkinides V, *et al*. Cancer disparities by race/ethnicity and socioeconomic status. *CA Cancer J Clin* 2004;54:78–93.
- Lal A, Erondu NA, Heymann DL, *et al*. Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage. *Lancet* 2021;397:61–7.
- Lal A, Abdalla SM, Chattu VK, *et al*. Pandemic preparedness and response: exploring the role of universal health coverage within the global health security architecture. *Lancet Glob Health* 2022;10:e1675–83.
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process -- first American Cancer Society Award Lecture on cancer epidemiology and prevention. *Cancer Res* 1992;52:6735–40.
- Plummer M, de Martel C, Vignat J, *et al*. Global burden of cancers attributable to infections in 2012: a synthetic analysis. *Lancet Glob Health* 2016;4:e609–16.
- Yang L, Kartsonaki C, Yao P, *et al*. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. *The Lancet Public Health* 2021;6:e888–96.
- Sugano K, Tack J, Kuipers EJ, *et al*. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* 2015;64:1353–67.
- Chiang T-H, Cheng H-C, Chuang S-L, *et al*. Mass screening and eradication of Helicobacter pylori as the policy recommendations for gastric cancer prevention. *J Formos Med Assoc* 2022;121:2378–92.
- Malfertheiner P, Megraud F, Rokkas T, *et al*. Management of Helicobacter pylori infection: the Maastricht VI/florence consensus report. *Gut* 2022;71:1724–62.
- Chiang T-H, Chang W-J, Chen SL-S, *et al*. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on matsu islands. *Gut* 2021;70:243–50.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, *et al*. Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. *JAMA Oncol* 2019;5:1749–68.
- Rabeneck L, Lansdorp-Vogelaar I. Assessment of a cancer screening program. *Best Pract Res Clin Gastroenterol* 2015;29:979–85.
- Arnold M, Moore SP, Hassler S, *et al*. The burden of stomach cancer in Indigenous populations: a systematic review and global assessment. *Gut* 2014;63:64–71.
- Bair M-J, Chuang S-L, Lei W-Y, *et al*. Planning mass eradication of Helicobacter pylori infection for Indigenous Taiwanese peoples to reduce gastric cancer. *J Gastroenterol Hepatol* 2020;35:609–16.
- Council of Indigenous Peoples. The tribes in Taiwan. Available: <https://www.cip.gov.tw/en/tribe/grid-list/index.html?cumid=5DD9C4959C302B9FD0636733C6861689> [Accessed 26 Dec 2022].
- Bernstein ES. *Organizational behavior reading; Leading teams (Core. Curriculum)*. Harvard Business School Publishing, 2016.
- Health Promotion Administration, Ministry of Health and Welfare, Taiwan. The gastric cancer screening and tracing system. Available: <https://portal.hpa.gov.tw/Web/Notice.aspx> [Accessed 26 Dec 2022].
- Lee Y-C, Chiang T-H, Chiu H-M, *et al*. Community-Based gastric cancer screening coupled with a national colorectal cancer screening program: baseline results. *Gastroenterology* 2021;160:2159–61.
- Lee Y-C, Lin J-T, Wu H-M, *et al*. Cost-Effectiveness analysis between primary and secondary preventive strategies for gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:875–85.
- Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. *Am J Gastroenterol* 2005;100:2083–99.
- Yokota S, Konno M, Fujiwara S, *et al*. Intrafamilial, preferentially mother-to-child and intrasposal, Helicobacter pylori infection in Japan determined by multilocus sequence typing and random amplified polymorphic DNA fingerprinting. *Helicobacter* 2015;20:334–42.
- Zhao J-B, Yuan L, Yu X-C, *et al*. Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: a systematic review and meta-analysis. *Helicobacter* 2021;26:e12793.
- Ding S-Z, Du Y-Q, Lu H, *et al*. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 edition). *Gut* 2022;71:238–53.
- Lee J-Y. An index case method for detecting Helicobacter pylori infection: a pilot study in wulai district [Master Thesis - Practicum Report]. College of Public Health, National Taiwan University, 2020.
- Best LM, Takwoingi Y, Siddique S, *et al*. Non-Invasive diagnostic tests for Helicobacter pylori infection. *Cochrane Database Syst Rev* 2018;3:CD012080.
- Liou J-M, Chen C-C, Chen M-J, *et al*. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *The Lancet* 2013;381:205–13.
- Yu J, Yang P, Qin X, *et al*. Impact of smoking on the eradication of Helicobacter pylori. *Helicobacter* 2022;27:e12860.
- Liou J-M, Malfertheiner P, Lee Y-C, *et al*. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. *Gut* 2020;69:2093–112.
- Graham DY, Moss SF. Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why. *Am J Gastroenterol* 2022;117:524–8.
- Liou J-M, Fang Y-J, Chen C-C, *et al*. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *Lancet* 2016;388:2355–65.
- Chiu SYH, Chen LS, Yen AMF, *et al*. Population-Based proband-oriented pedigree information system: application to hypertension with population-based screening data (KCIS No. 25). *JAM Med Inform Assoc* 2012;19:102–10.
- Dreyer JT. Voice from a native land – Taiwan today. Available: <https://taiwantoday.tw/news.php?post=36625&unit=29,45> [Accessed 5 Apr 2023].
- Huang RJ, Epplein M, Hamashima C, *et al*. An approach to the primary and secondary prevention of gastric cancer in the United States. *Clin Gastroenterol Hepatol* 2022;20:2218–28.
- Buchholz K, Statista. The global chasm in Indigenous life expectancy. Available: <https://www.statista.com/chart/19674/indigenous-life-expectancy-by-gender/> [Accessed 27 Dec 2022].
- Zhou X-Z, Lyu N-H, Zhu H-Y, *et al*. Large-Scale, National, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention. *Gut* 2023;72:855–69.
- Tien H-Y. Investigation of health-promotion lifestyles and associated factors between patients with and without Helicobacter pylori infection [Master Thesis]. Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, 2021.
- DuBois S, Kearney DJ. Iron-Deficiency anemia and Helicobacter pylori infection: a review of the evidence. *Am J Gastroenterol* 2005;100:453–9.
- Merrell DS, Thompson LJ, Kim CC, *et al*. Growth phase-dependent response of Helicobacter pylori to iron starvation. *Infect Immun* 2003;71:6510–25.
- Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. *Clinical Gastroenterology and Hepatology* 2014;12:177–186.
- Lee YC, Dore MP, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. *Annu Rev Med* 2022;73:183–95.
- World Health Organization. A short guide to cancer screening. 2022. Available: <https://apps.who.int/iris/bitstream/handle/10665/351396/9789289057561-eng.pdf> [Accessed 27 Dec 2022].
- Park JY, Herrero R. Recent progress in gastric cancer prevention. *Best Pract Res Clin Gastroenterol* 2021;50–51:101733.

APPENDIX

This appendix has been provided by the authors to give readers additional information about the work. Supplement to: Lei WY, Lee JY, Chuang SL, *et al.* Eradicating *Helicobacter pylori* via ¹³C-urea breath screening to prevent gastric cancer in indigenous communities: A population-based study and development of a family index-case method

Item	Description
Supplementary Table 1	Baseline characteristics of participants for the family history, medical history, and ethnic groups, with relationship to <i>Helicobacter pylori</i> infection
Supplementary Table 2	The infection-pedigree relationships in a representative Taiwanese indigenous township in the proof-of-concept study. (A) <i>H. pylori</i> infection status of the index case and his/her family members, and (B) <i>H. pylori</i> infection status in the consanguinity relationship
Supplementary Table 3	The risk of <i>H. pylori</i> infection according to the status of the index case and his/her family members. (A) Results in the proof-of-concept study and (B) results in the mass screening setting
Supplementary Table 4	Referral-to-treatment rate in the participants who tested positive for <i>H. pylori</i> infection and results of the first-line eradication treatment
Supplementary Table 5	Reinfection rates of <i>H. pylori</i> in the Taiwanese indigenous communities
Supplementary Fig. 1	The workflow of the screening and eradication program
Supplementary Fig. 2	Risk factors associated with the 797 treatment failure among 4601 subjects who received the first-line treatment for <i>H. pylori</i> infection according to the per-protocol analyses
Supplementary Fig. 3	Risk factors associated with the 25 reinfection of <i>H. pylori</i> after successful eradication in 498 subjects

Supplementary Table 1. Baseline characteristics of participants for the family history, medical history, and ethnic groups, with relationship to *Helicobacter pylori* infection

Baseline characteristics	Indigenous peoples (N=8852)		Non-indigenous peoples (N=6205)	
	No. of subjects	No. of <i>H. pylori</i> carriers (%)	No. of subjects	No. of <i>H. pylori</i> carriers (%)
	8852	5055 (57.1)	6205	1588 (25.6)
Family history				
Family history of <i>H. pylori</i> infection	681	360 (52.9)	437	117 (26.8)
Family history of peptic ulcer	1135	630 (55.5)	695	177 (25.5)
Family history of gastric cancer	489	274 (56.0)	139	47 (33.8)
Medical history				
Personal history of peptic ulcer	1075	538 (50.0)	446	101 (22.6)
Previous <i>H. pylori</i> infection	710	172 (24.2)	374	56 (15.0)
Non-steroidal anti-inflammatory drug user	1958	1132 (57.8)	1343	316 (23.5)
Anti-platelet agent user	130	69 (53.1)	58	18 (31.0)
Anti-coagulant user	97	51 (52.6)	43	13 (30.2)
Diabetic drug user	754	463 (61.4)	223	82 (36.8)
Iron supplement user	113	64 (56.6)	53	9 (17.0)
Ethnic groups*				
Amis	2683	1331 (49.6)	-	-
Bunun	1394	940 (67.4)	-	-
Cou	12	9 (75)	-	-
Hla'alua	22	13 (59.1)	-	-

Kanakanavu	28	21 (75)	-	-
Kebalan	37	20 (54.1)	-	-
Paiwan	1168	656 (56.2)	-	-
Puyuma	300	169 (56.3)	-	-
Rukai	302	189 (62.6)	-	-
Sakizaya	23	10 (43.5)	-	-
Say-Siyat	5	1 (20)	-	-
Seediq	96	61 (63.5)	-	-
Tao/Yami	193	100 (51.8)	-	-
Taroko	1669	1000 (59.9)	-	-
Tayal	822	492 (59.9)	-	-
Missing values	98	43 (43.9)	-	-

* There were 16 officially recognized ethnic groups in Taiwanese indigenous peoples. Every ethnic group has its own distinct culture, language, customs and social structure.

Supplementary Table 2. The infection-pedigree relationships in a representative Taiwanese indigenous township in the proof-of-concept study

(A) *H. pylori* infection status of the index case and his/her family members

Family no.	Family name	Index case (age)	Family member (age)					
			●40	■45	●21			
1	C1	●22	●40	■45	●21			
2	C10	■49	●22	■29	□28	●52	○24	●21
3	C11	●30	●63	■25	■67	■31	■43	
4	C12	■64	■41	●50	○63			
5	C14	●54	■57	●32	●54	○45	●24	
6	C16	○48	■65	□20	■55	□27		
7	C17	■46	□16	○38				
8	C18	○55	■60	●23	□30	○34		
9	C19	■64	○62					
10	C2	○56	■54	●54				
11	C20	■58	○55	●36	□37	■34		
12	C21	●56	□19	□55				
13	C22	●70	□36	○35				
14	C23	●37	○28					
15	C24	●49	□50	●29				
16	C25	●56	○27	■32	■31	■38		
17	C27	■62	■29	●60	□40			
18	C28	■26	■49	●26				
19	C29	■62	●66	■37				
20	C3	●54	□29	■60	□31	○28		
21	C30	■42	○28					
22	C31	■44	●55	■29				
23	C32	■61	●60					
24	C33	□30	○28	○60				
25	C4	○32	○59	■34				

26	C5	○65	■66					
27	C6	□38	●38	○70				
28	C7	●43	■43	○76	●31			
29	C8	□58	■24					
30	F1	●53	□59	●29	■26			
31	F10	●52	■40	●34	●37			
32	F11	■27	■53					
33	F12	■69	●61	■45				
34	F13	●70	●41	●46	□44	■45		
35	F14	■86	□60	○49	●48	○85	■58	
36	F15	●37	□68	■35	■46	●61		
37	F17	●53	●26	●21				
38	F2	○68	■67					
39	F3	●42	●33	●66				
40	F4	●40	□43					
41	F5	●43	○15	■76	□40			
42	F6	□52	○47					
43	F9	■72	●38	■50	●48	●66	□45	
44	S1	○72	●52	○50				
45	S2	■34	□32	■31	●53	●27		
46	W1	●52	■55	■24	■28	●26		
47	W12	■67	●39					
48	W15	●56	■61	■38	■35	○35		
49	W16	○53	■31	●32	●29	●31		
50	W17	○58	■36	■61				
51	W18	○32	■39	■63				
52	W19	■48	●11	■18				
53	W20	○58	●33					
54	W21	●51	○24	■28				

55	W22	○31	○36	●23	○57	□53		
56	W23	□50	○50	□23				
57	W28	●42	■47	●44	○43			
58	W3	○62	□65	■30				
59	W30	○54	○81	○29	■61	○32		
60	W31	●58	■61					
61	W32	□43	■79	●69	□47	○35	□27	
62	W33	○55	○22	□57				
63	W35	●61	■61	□27				
64	W36	○50	□22	○25	■54			
65	W37	●61	■40	●36				
66	W38	■56	●81	□88				
67	W40	□61	■30	●28				
68	W41	■71	●46					
69	W6	○33	○61	■69	○41			
70	W7	●57	●68	■63				
71	W8	●46	■53	□18	●20			
72	W9	●61	□58	●35				

A square indicates the male sex and a circle indicates the female sex. The black color indicates the positivity for the *H. pylori* infection while the white color indicates negativity.

* In the proof-of-concept study, there was no age restriction for enrollment.

(B) *H. pylori* infection status in the consanguinity relationship

	Spouse +	Spouse –
Index case +	19	11
Index case –	8	5
	Sibling +	Sibling –
Index case +	13	5
Index case –	5	4
	Parent-child +	Parent-child –
Index case +	48	19
Index case –	14	16

+ indicates *H. pylori* infection; – indicates *H. pylori* non-infection

Supplementary Table 3. The risk of *H. pylori* infection among the family members according to the status of the index case and his/her family members

(A) Results in the proof-of-concept study

	OR	95% CI	aOR*	95% CI
Status of the index case[†]				
¹³ C UBT results				
Negative index case	1		1	
Positive index case	1.89	0.97–3.66	1.98	1.03–3.80
Age				
Increase of 10 years	0.99	0.77–1.28	0.96	0.74–1.25
Sex				
Female	1		1	
Male	0.81	0.43–1.55	0.55	0.27–1.10
Smoking				
Never	1		1	
Former	2.51	1.05–6.05	2.87	1.17–7.02
Current	2.98	1.43–6.23	2.87	1.31–6.33

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; UBT, urea breath test

* Adjusted for the age, sex, and the smoking habit in the generalized estimated equation models.

[†] All the participants in the proof-of-concept study were indigenous.

(B) Results in the mass screening setting

	OR	95% CI	aOR*	95% CI
Status of the index case				
¹³ C UBT results				
Negative index case	1		1	
Positive index case	2.28	1.90–2.74	1.95	1.61–2.36
Indigenous status [†]				
Non-indigenous	1		1	
Indigenous	2.68	2.20–3.27	2.31	1.88–2.84
Age				
Increase of 10 years	1.22	1.14–1.31	1.22	1.13–1.32
Sex				
Female	1		1	
Male	1.28	1.08–1.52	1.15	0.95–1.39
Smoking				
Never	1		1	
Former	1.38	1.07–1.77	1.13	0.85–1.50
Current	1.84	1.49–2.27	1.51	1.20–1.90

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; UBT, urea breath test

* Adjusted for the age, sex, smoking habit, and the indigenous status in the generalized estimated equation models.

[†] Participants in the mass screening setting included both indigenous and non-indigenous peoples.

Supplementary Table 4. The referral-to-treatment rate in the participants who tested positive for *H. pylori* infection and results of the first-line eradication treatment

	No. of participants	Test positive, no. (%)	First-line treatment		
			Treat, no. (%)	Re-test, no. (%)	Re-test positive, no. (%)
Indigenous peoples					
Male					
20–39	1197	648 (54.1)	499 (77.0)	417 (83.6)	110 (26.4)
40–60	1947	1198 (61.5)	974 (81.3)	843 (86.6)	166 (19.7)
Subtotal	3144	1846 (58.7)	1473 (79.8)	1260 (85.5)	276 (21.9)
Female					
20–39	2071	1101 (53.2)	876 (79.6)	733 (83.7)	206 (28.1)
40–60	3637	2108 (58.0)	1802 (85.5)	1573 (87.3)	350 (22.3)
Subtotal	5708	3209 (56.2)	2678 (83.5)	2306 (86.1)	556 (24.1)
Both sexes					
20–39	3268	1749 (53.5)	1375 (78.6)	1150 (83.6)	316 (27.5)
40–60	5584	3306 (59.2)	2776 (84.0)	2416 (87.0)	516 (21.4)
Total	8852	5055 (57.1)	4151 (82.1)	3566 (85.9)	832 (23.3)
Non-indigenous peoples					
Male					
20–39	856	148 (17.3)	123 (83.1)	110 (89.4)	19 (17.3)
40–60	1457	461 (31.6)	394 (85.5)	354 (89.8)	64 (18.1)
Subtotal	2313	609 (26.3)	517 (84.9)	464 (89.7)	83 (17.9)
Female					
20–39	1293	217 (16.8)	179 (82.5)	165 (92.2)	27 (16.4)
40–60	2599	762 (29.3)	646 (84.8)	577 (89.3)	82 (14.2)
Subtotal	3892	979 (25.2)	825 (84.3)	742 (89.9)	109 (14.7)
Both sexes					
20–39	2149	365 (17.0)	302 (82.7)	275 (91.1)	46 (16.7)
40–60	4056	1223 (30.2)	1040 (85.0)	931 (89.5)	146 (15.7)
Total	6205	1588 (25.6)	1342 (84.5)	1206 (89.9)	192 (15.9)
Overall	15057	6643 (44.1)	5493 (82.7)	4772 (86.9)	1024 (21.5)


Supplemental Table 5. Reinfection rates of *H. pylori* in the Taiwanese indigenous communities

Characteristics	No. of subjects	No. of reinfection	Mean follow-up time (years)	Total follow-up time (person-years)	Reinfection rate (%)
Total	498	25	3.15	1569.02	1.59
Infection naïve	381	23	3.25	1238.36	1.86
Previous infected individuals	290	18	3.11	902.37	1.99
Age, in years					
20–29	39	3	3.03	118.22	2.54
30–39	123	6	3.10	381.61	1.57
40–49	166	8	3.20	531.27	1.51
50+	170	8	3.16	537.92	1.49
Sex					
Male	151	11	3.09	467.25	2.35
Female	347	14	3.18	1101.77	1.27
Medical history					
Family history of <i>H. pylori</i> infection	35	1	3.12	109.23	0.92
Family history of peptic ulcer	82	1	3.19	261.98	0.38
Family history of gastric cancer	30	3	3.36	100.72	2.98
Personal history of peptic ulcer	67	4	3.24	217.16	1.84
Previous <i>H. pylori</i> infection	36	1	3.28	117.96	0.85
Non-steroidal anti-inflammatory drug	100	8	3.15	315.40	2.54
Diabetic drug	28	2	3.26	91.37	2.19
Iron supplement	4	0	3.40	13.61	0.00
Social habit					
Smoking					
Current	63	6	3.20	201.80	2.97
Former	58	6	3.06	177.60	3.38
Never	377	13	3.16	1189.62	1.09
Alcohol use					
Current	280	20	3.20	896.49	2.23
Former	22	0	3.14	69.14	0.00

	Never	196	5	3.08	603.39	0.83
Betel nut chewing	Current	105	11	3.20	336.43	3.27
	Former	42	4	3.22	135.08	2.96
	Never	351	10	3.13	1097.51	0.91


Supplementary Fig. 1. The workflow of the screening and eradication program

Following the principles of an organized screening program, four quality indicators, including the invitation rate, positivity rate, referral-to-treatment rate, and the eradication rate were monitored periodically in an on-line system. The orange color indicates the *H. pylori* carriers and the blue indicates the non-carriers or those who received successful eradication treatments.



Supplementary Fig. 2. Risk factors associated with the 797 treatment failure among 4601 subjects who received the first-line treatment for *H. pylori* infection according to the per-protocol analyses

The multivariable logistic regression model adjusts for all variables shown in the forest plot. An odds ratio greater than 1.0 indicates an increased risk of treatment failure. The use of anti-platelet agent is not included in the multivariate analyses due to the small case numbers. CI = confidence interval.



Supplementary Fig. 3. Risk factors associated with the 25 reinfection of *H. pylori* after successful eradication in 498 subjects

A rate ratio greater than 1.0 indicates an increased risk of the reinfection. Results of the Poisson regression models are shown in the forest plot. An odds ratio greater than 1.0 indicates an increased risk of reinfection. CI = confidence interval. Owing to the small reinfection case number, only univariate analyses are performed. There was no case of reinfection in the former alcohol users.

